The present data show that there are consistent differences between immunological responder and non-responder patients to TRIMEL-loaded DC immunotherapy, using CXCR4 and CD32 as tentative biomarkers, although, we cannot discard the dependence of other potential additional factors, as exome mutations, polymorphisms in immune related genes or immunological changes induced by particular tumor mutations in each patient. This evidence concerns the gene FCGR2A and neoplasm.